Michelle A. Detry
A5069999714- COVID-19 Clinical Research Studies
- Sepsis Diagnosis and Treatment
- Long-Term Effects of COVID-19
- Amyotrophic Lateral Sclerosis Research
- Chronic Lymphocytic Leukemia Research
- COVID-19 and Mental Health
- Receptor Mechanisms and Signaling
- Venous Thromboembolism Diagnosis and Management
- Acute Lymphoblastic Leukemia research
- Cancer Genomics and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Lymphoma Diagnosis and Treatment
- Asthma and respiratory diseases
- Statistical Methods in Clinical Trials
- Pancreatic and Hepatic Oncology Research
- Genomics, phytochemicals, and oxidative stress
- Bladder and Urothelial Cancer Treatments
- Heart Failure Treatment and Management
- SARS-CoV-2 and COVID-19 Research
- Respiratory and Cough-Related Research
- DNA Repair Mechanisms
- Intensive Care Unit Cognitive Disorders
- Hepatitis C virus research
- Inhalation and Respiratory Drug Delivery
- Frailty in Older Adults
Berry & Associates (United States)
2014-2025
Association Clinique et Thérapeutique Infantile du Val de Marne
2022-2023
Medical Research Institute of New Zealand
2023
University of Auckland
2023
Middlemore Hospital
2023
Auckland City Hospital
2023
University Health Network
2021
St. Michael's Hospital
2021
Health Sciences Centre
2021
Sunnybrook Health Science Centre
2021
The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.We evaluated tocilizumab and sarilumab an ongoing international, multifactorial, adaptive platform trial. Adult Covid-19, within 24 hours after starting organ support the intensive care unit (ICU), were randomly assigned to receive (8 mg per kilogram body weight), (400 mg), or standard (control). primary outcome was respiratory cardiovascular support-free days, on...
Fludarabine and cyclophosphamide (FC), which are active in treatment of chronic lymphocytic leukemia (CLL), synergistic with the monoclonal antibody rituximab vitro lymphoma cell lines. A chemoimmunotherapy program consisting fludarabine, cyclophosphamide, (FCR) was developed goal increasing complete remission (CR) rate previously untreated CLL patients to >/= 50%.We conducted a single-arm study FCR as initial therapy 224 progressive or advanced CLL. Flow cytometry used measure residual...
Thrombosis and inflammation may contribute to morbidity mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill Covid-19.
<h3>Importance</h3> Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. <h3>Objective</h3> To determine whether hydrocortisone improves outcome patients with COVID-19. <h3>Design, Setting, and Participants</h3> An ongoing adaptive platform trial testing multiple interventions within therapeutic domains, example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 June 17, 2020, 614 adult suspected confirmed COVID-19 were enrolled...
Thrombosis and inflammation may contribute to the risk of death complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation improve outcomes in noncritically ill who are hospitalized Covid-19.In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned were Covid-19 not critically (which was defined as an absence critical care-level organ support at enrollment) receive pragmatically regimens either...
There is broad interest in improved methods to generate robust evidence regarding best practice, especially settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale design of a large, international trial that combines features adaptive platform trials with pragmatic point-of-care determine treatment strategies for patients admitted an intensive care unit severe community-acquired pneumonia. The uses novel design, entitled...
Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications Network Open Cardiology Dermatology Health Forum Internal Medicine Neurology Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning /...
<h2>Summary</h2><h3>Background</h3> Azithromycin, an antibiotic with potential antiviral and anti-inflammatory properties, has been used to treat COVID-19, but evidence from community randomised trials is lacking. We aimed assess the effectiveness of azithromycin suspected COVID-19 among people in who had increased risk complications. <h3>Methods</h3> In this UK-based, primary care, open-label, multi-arm, adaptive platform trial interventions against at adverse clinical course (PRINCIPLE),...
Background: Although research focused on African Americans with mental illness has been increasing, few researchers have addressed gender and age differences in beliefs, attitudes, coping. Objective: The aim of this study was to examine Americans’ beliefs about illness, attitudes toward seeking health services, preferred coping behaviors whether these variables differ by age. Methods: An exploratory, cross-sectional survey design used. Participants were 272 community-dwelling aged 25–72...
Abstract Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and sarilumab an ongoing international, multifactorial, adaptive platform trial. Adult Covid-19, within 24 hours commencing organ support intensive care unit, were randomized to receive either (8mg/kg) or (400mg) standard (control). primary outcome was ordinal scale combining in-hospital mortality (assigned −1)...
Platelets represent a potential therapeutic target for improved clinical outcomes in patients with COVID-19.
Importance Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity treatment effect (HTE) across individuals. Better understanding HTE could facilitate individualized decision-making. Objective To evaluate for and compare approaches assessing HTE. Design, Setting, Participants Exploratory analysis a multiplatform adaptive RCT vs usual care pharmacologic thromboprophylaxis 3320 enrolled...
No AccessJournal of UrologyAdult urology1 Mar 2006The Case for Early Cystectomy in the Treatment Nonmuscle Invasive Micropapillary Bladder Carcinomais corrected byErrata Ashish M. Kamat, Jason R. Gee, Colin P.N. Dinney, H. Barton Grossman, David A. Swanson, Randall E. Millikan, Michelle Detry, Tracy L. Robinson, and Louis Pisters KamatAshish Kamat Department Urology, The University Texas D. Anderson Cancer Center, Houston, , GeeJason Gee DinneyColin Dinney GrossmanH. Grossman SwansonDavid...
Background: The safety, effectiveness and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, in patients the community who are multiply-vaccinated at increased risk morbidity mortality from COVID-19, has not been established. We aimed to determine whether molnupiravir added usual care reduced hospital admissions/deaths among people higher here report our preliminary analyses.Methods: Participants this UK multicentre, open-label, adaptive, multi-arm, platform,...
The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.